CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: DRAXIN (ImmuneEditome ID:374946)

1. Gene summary of enriched editing regions for DRAXIN

check button Gene summary
Gene informationGene symbol

DRAXIN

Gene ID

374946

GeneSynonymsAGPA3119|C1orf187|UNQ3119|neucrin
GeneCytomap

1p36.22

GeneTypeprotein-coding
GeneDescriptiondraxin|dorsal repulsive axon guidance protein|neural tissue-specific cysteine-rich protein
GeneModificationdate20230329
UniprotIDQ8NBI3
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr1:11721665-11723903:+ENST00000294485.5ENSG00000162490.6DRAXINUTR3MER5B,AluSx,AluSq,AluSx1,MER58B,MIR,Plat_L3chr1:11721665-11723903:+.alignment
chr1:11725083-11725340:+ENST00000294485.5ENSG00000162490.6DRAXINUTR3AluJr,MER5A1chr1:11725083-11725340:+.alignment


Top

2. Tumor-specific enriched editing regions for DRAXIN


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for DRAXIN


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr1:11721665-11723903:+GBMEERENSG00000188070,C11orf95-0.56064.0791e-071.1044e-07-0.4566imageNADAR;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX42;DGCR8;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;NONO;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;ZNF184NAMonocytesGSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr1:11721665-11723903:+GBMEERENSG00000176887,SOX11-0.55585.7183e-078.5198e-07-0.4268imageNADAR;DGCR8;ELAVL1;ELAVL3;FBL;FMR1;FUS;HNRNPA2B1;HNRNPM;IGF2BP2;MOV10;RBFOX2;TAF15;TARDBP;TROVE2NAT_cells_follicular_helperGSVA_HALLMARK_BILE_ACID_METABOLISM
chr1:11721665-11723903:+GBMEERENSG00000278129,ZNF8-0.55476.3413e-071.0573e-09-0.5154imageNADAR;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28A;LIN28B;MOV10;NONO;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;ZNF184NAMonocytesGSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr1:11721665-11723903:+GBMEERENSG00000105426,PTPRS-0.54221.2865e-061.0227e-07-0.4577imageNACIN1;ADAR;AUH;BCCIP;BUD13;CBX7;CNBP;CPSF6;CSTF2T;DDX42;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;NONO;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;RNF219;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;ZNF184PTPRSMonocytesGSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr1:11721665-11723903:+GBMEERENSG00000178409,BEND3-0.53352.8131e-063.9463e-09-0.4999imageNADAR;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;NONO;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;ZNF184NAT_cells_follicular_helperGSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr1:11721665-11723903:+GBMEERENSG00000169951,ZNF764-0.52883.6645e-061.1498e-07-0.4561imageNAUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX42;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LARP7;LIN28;LIN28B;LSM11;MOV10;NONO;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;RNF219;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;TAF15;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;ZNF184NAMonocytesGSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr1:11721665-11723903:+GBMEERENSG00000121210,KIAA0922-0.52654.1660e-062.4224e-09-0.5057imageNACIN1;ADAR;AUH;BCCIP;BUD13;CBX7;CNBP;CPSF6;CSTF2T;DDX42;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF7;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;ZNF184NAMonocytesGSVA_HALLMARK_BILE_ACID_METABOLISM
chr1:11721665-11723903:+GBMEERENSG00000127616,SMARCA4-0.52235.2570e-064.4714e-08-0.4690imageNACIN1;ADAR;AUH;BCCIP;BUD13;CBX7;CNBP;CPSF6;CSTF2T;DDX42;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;NONO;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;ZNF184SMARCA4MonocytesGSVA_HALLMARK_MITOTIC_SPINDLE
chr1:11721665-11723903:+GBMEERENSG00000129351,ILF3-0.52225.3753e-061.7327e-09-0.5097imageNACIN1;ADAR;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX42;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;NONO;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;ZNF184ILF3MonocytesGSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr1:11721665-11723903:+GBMEERENSG00000177733,HNRNPA0-0.51327.1840e-061.6522e-08-0.4820imageNACIN1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX42;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;NONO;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;ZNF184NAMonocytesGSVA_HALLMARK_G2M_CHECKPOINT
chr1:11725083-11725340:+GBMEERENSG00000196132,MYT1-0.42521.0865e-043.3410e-07-0.4140imageNHNRNPCNAMonocytesGSVA_HALLMARK_BILE_ACID_METABOLISM
chr1:11725083-11725340:+GBMEERENSG00000077279,DCX-0.40542.3620e-045.0919e-07-0.4081imageNNNAMacrophages_M0GSVA_HALLMARK_BILE_ACID_METABOLISM
chr1:11725083-11725340:+GBMEERENSG00000072832,CRMP1-0.39625.3661e-042.1372e-07-0.4202imageNHNRNPCNAMonocytesGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr1:11725083-11725340:+GBMEERENSG00000130224,LRCH2-0.37927.3127e-049.5341e-08-0.4310imageNHNRNPCNAT_cells_follicular_helperGSVA_HALLMARK_P53_PATHWAY
chr1:11725083-11725340:+GBMEERENSG00000171033,PKIA-0.38777.7131e-046.6545e-07-0.4042imageNHNRNPCNAT_cells_CD4_memory_activatedGSVA_HALLMARK_PANCREAS_BETA_CELLS
chr1:11725083-11725340:+GBMEERENSG00000188070,C11orf95-0.38567.7940e-046.1985e-07-0.4053imageNHNRNPCNAMonocytesGSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr1:11725083-11725340:+GBMEERENSG00000167107,ACSF20.38168.1727e-048.0015e-080.4333imageNHNRNPCACSF2T_cells_CD8GSVA_HALLMARK_BILE_ACID_METABOLISM
chr1:11725083-11725340:+GBMEERENSG00000130303,BST20.38268.6639e-044.5463e-100.4946imageNHNRNPCBST2Macrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr1:11725083-11725340:+GBMEERENSG00000108679,LGALS3BP0.37211.4687e-033.4266e-080.4442imageNHNRNPCLGALS3BPMacrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr1:11725083-11725340:+GBMEERENSG00000188322,SBK1-0.36901.5501e-036.3734e-07-0.4049imageNHNRNPCNAT_cells_follicular_helperGSVA_HALLMARK_COAGULATION

More results



Top

4. Enriched editing regions and immune related splicing for DRAXIN


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr1:11721665-11723903:+
GBMEERESENSG00000197535.10chr1552336462:52336556:52337809:52337884:52340195:523403940.32479.2087e-031.9819e-050.4127imageNACIN1;ADAR;BUD13;CNBP;CSTF2T;DGCR8;DHX9;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR2;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;LIN28;LIN28A;LIN28B;MOV10;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;SF3B4;SRSF1;TAF15;TARDBP;U2AF1;U2AF2;UPF1;YTHDF1;ZNF184NAMonocytesGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr1:11721665-11723903:+
GBMEERIRENSG00000182196.9chr12122980927:122980987:122981128:122981205-0.41159.4013e-042.6009e-07-0.4734imageNACIN1;ADAR;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX42;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MOV10;NONO;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;ZNF184NAMonocytesGSVA_HALLMARK_FATTY_ACID_METABOLISM
chr1:11725083-11725340:+
GBMEERESENSG00000080603.12chr1630722124:30722286:30722562:30722748:30722962:30723229-0.38534.7525e-054.1553e-07-0.4683imageNHNRNPCNAT_cells_gamma_deltaGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr1:11725083-11725340:+
GBMEERESENSG00000144354.9chr2173358714:173358837:173359254:173359491:173363225:173363462-0.36111.5728e-036.6264e-06-0.4063imageNHNRNPCNAT_cells_follicular_helperGSVA_HALLMARK_SPERMATOGENESIS
chr1:11721665-11723903:+
GBMEERMEXENSG00000113648.12chr5135345967:135346057:135350822:135350913:135352945:135353042:135360496:1353606040.40635.4833e-031.3773e-060.4194imageNACIN1;ADAR;AUH;BCCIP;BUD13;CBX7;CNBP;CPSF6;CSTF2T;DDX42;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;NONO;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;ZNF184NAMonocytesGSVA_HALLMARK_E2F_TARGETS
chr1:11721665-11723903:+
GBMEERMEXENSG00000113648.12chr5135345967:135346057:135350822:135350913:135352945:135360054:135360496:1353606040.40635.4833e-031.3772e-060.4194imageNACIN1;ADAR;AUH;BCCIP;BUD13;CBX7;CNBP;CPSF6;CSTF2T;DDX42;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;NONO;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;ZNF184NAMonocytesGSVA_HALLMARK_E2F_TARGETS
chr1:11721665-11723903:+
GBMEERIRENSG00000005483.15chr7105107899:105110368:105110770:1051108670.38485.6766e-034.2081e-060.4108imageNACIN1;ADAR;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX42;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;NONO;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;ZNF184NAMonocytesGSVA_HALLMARK_DNA_REPAIR
chr1:11721665-11723903:+
GBMEERIRENSG00000204220.5chr633289595:33289628:33289769:33289920-0.43351.1590e-034.1460e-06-0.4063imageNACIN1;AUH;BCCIP;BUD13;CPSF6;CSTF2T;DDX42;DGCR8;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;NONO;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;ZNF184NAMacrophages_M0GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr1:11721665-11723903:+
GBMEERMEXENSG00000113648.12chr5135345967:135346057:135350782:135350913:135352945:135353042:135360496:1353606040.40116.7250e-037.2601e-070.4293imageNACIN1;ADAR;AUH;BCCIP;BUD13;CBX7;CNBP;CPSF6;CSTF2T;DDX42;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;NONO;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;ZNF184NAMonocytesGSVA_HALLMARK_E2F_TARGETS
chr1:11721665-11723903:+
GBMEERMEXENSG00000113648.12chr5135345967:135346057:135350782:135350913:135352945:135360054:135360496:1353606040.40116.7250e-037.2595e-070.4293imageNACIN1;ADAR;AUH;BCCIP;BUD13;CBX7;CNBP;CPSF6;CSTF2T;DDX42;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;NONO;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;ZNF184NAMonocytesGSVA_HALLMARK_E2F_TARGETS

More results



Top

5. Enriched editing regions and immune infiltration for DRAXIN


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr1:11725083-11725340:+BRCAEERT_cells_CD4_memory_activated1.0497e-020.3281image
ENSG00000162490.6,DRAXINBRCAEAGT_cells_CD4_memory_activated1.9792e-020.2863image
chr1:11721665-11723903:+GBMEERMacrophages_M01.4192e-03-0.2846image
chr1:11725083-11725340:+GBMEERMacrophages_M04.2822e-02-0.1708image
ENSG00000162490.6,DRAXINGBMEAGMacrophages_M04.3921e-03-0.2361image
chr1:11721665-11723903:+LGGEERB_cells_memory2.4741e-040.3355image
ENSG00000162490.6,DRAXINLGGEAGPlasma_cells5.8902e-030.1851image
chr1:11721665-11723903:+SARCEERNK_cells_activated2.8308e-020.4476image
chr1:11725083-11725340:+SARCEERT_cells_CD4_naive2.3684e-02-0.2994image
chr1:11721665-11723903:+SKCMEERT_cells_CD4_naive4.2943e-060.6837image
chr1:11725083-11725340:+SKCMEERB_cells_naive8.4737e-03-0.3649image
ENSG00000162490.6,DRAXINSKCMEAGB_cells_naive2.5600e-03-0.3888image
ENSG00000162490.6,DRAXINTGCTEAGT_cells_CD4_memory_resting2.5795e-030.4212image


Top

6. Enriched editing regions and immune gene sets for DRAXIN


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr1:11725083-11725340:+BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.1145e-030.4108image
ENSG00000162490.6,DRAXINBRCAGSVA_HALLMARK_COMPLEMENTEAG7.3179e-040.4055image
ENSG00000162490.6,DRAXINGBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.4331e-050.3440image
chr1:11725083-11725340:+GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER6.4555e-060.3696image
chr1:11721665-11723903:+GBMGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER2.8634e-06-0.4077image
chr1:11725083-11725340:+LGGGSVA_HALLMARK_G2M_CHECKPOINTEER3.2105e-03-0.2106image
chr1:11721665-11723903:+LGGGSVA_HALLMARK_G2M_CHECKPOINTEER9.9351e-09-0.5032image
ENSG00000162490.6,DRAXINLGGGSVA_HALLMARK_E2F_TARGETSEAG9.2098e-05-0.2606image
chr1:11721665-11723903:+SARCGSVA_HALLMARK_DNA_REPAIREER3.5576e-020.4308image
ENSG00000162490.6,DRAXINSARCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.9934e-020.2998image
chr1:11725083-11725340:+SARCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.2101e-020.3303image
chr1:11725083-11725340:+SKCMGSVA_HALLMARK_PROTEIN_SECRETIONEER2.9827e-020.3045image
chr1:11721665-11723903:+SKCMGSVA_HALLMARK_UV_RESPONSE_DNEER4.2265e-03-0.4655image
ENSG00000162490.6,DRAXINTGCTGSVA_HALLMARK_GLYCOLYSISEAG1.0636e-04-0.5253image
ENSG00000162490.6,DRAXINTHCAGSVA_HALLMARK_IL2_STAT5_SIGNALINGEAG4.6043e-020.2237image


Top

7. Enriched editing regions and drugs for DRAXIN


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr1:11725083-11725340:+BRCAAZD6482EER6.6723e-03-0.3466image
ENSG00000162490.6,DRAXINBRCAAZD6482EAG1.2000e-03-0.3902image
ENSG00000162490.6,DRAXINGBMBI.D1870EAG5.5248e-060.3684image
chr1:11725083-11725340:+GBMBIBW2992EER6.9262e-04-0.2824image
chr1:11721665-11723903:+GBMBIBW2992EER1.7920e-06-0.4152image
chr1:11725083-11725340:+LGGJNK.Inhibitor.VIIIEER6.0945e-060.3183image
chr1:11721665-11723903:+LGGGefitinibEER5.4848e-07-0.4470image
ENSG00000162490.6,DRAXINLGGJNK.Inhibitor.VIIIEAG4.2867e-060.3043image
chr1:11721665-11723903:+SARCDMOGEER1.9040e-020.4748image
ENSG00000162490.6,DRAXINSARCJNK.Inhibitor.VIIIEAG1.0599e-02-0.3277image
chr1:11725083-11725340:+SARCBleomycinEER9.7287e-030.3397image
ENSG00000162490.6,DRAXINSKCMBX.795EAG1.4908e-020.3182image
chr1:11725083-11725340:+SKCMBX.795EER8.6945e-030.3638image
chr1:11721665-11723903:+SKCMGemcitabineEER4.1658e-040.5571image
ENSG00000162490.6,DRAXINTGCTDocetaxelEAG4.4428e-050.5488image
ENSG00000162490.6,DRAXINTHCAMetforminEAG4.9030e-030.3116image
chr1:11725083-11725340:+THCAGSK.650394EER5.3764e-030.3104image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType